| Symbol
| DRD4
| contributors: mct/npt - updated : 06-02-2018
|
| HGNC name
| dopamine receptor D4
|
| HGNC id
| 3025
|
| corresponding disease(s)
|
PTNS
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --low
|
|
by hypermethylation, DRD4 promoter methylation was significantly higher in AD patients than in controls  | |
| Susceptibility
|
to Gilles de la Tourette syndrome and a wide range of neuropsychiatric disorders to attention deficit hyperactivity disorder (ADHD), with preferential transmission of paternal alleles to dyslexia (DYX7) to migraine without aura to attention-deficit/hyperactivity disorder (ADHD) related to oxidative stress to schizophrenia to age related changes in brain glucose metabolism |
| Variant & Polymorphism
repeat
, other
| association with seven repeat allele (VNTR) in exon 3 in attention deficit hyperactivity syndrome |
|
exon 3 VNTR allele protecting against migraine without aura (DeSousa 2007) |
|
carriers of the 7R allele appear to be less sensitive to the effects of age on brain glucose metabolism |
|
male-specific association between DRD4 gene methylation and schizophrenia |
|
DRD4 GG genotype, that had been exposed to high DMP levels (more than the median), and had high HNE-MA levels had a significantly increased risk for developing ADHD |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cardiovascular | aquired | | |
| may be a potential therapeutic target to reduce the effects of insulin on artery remodeling |
| | | |
|
| Drd4 knock-out mice, when compared with wild-type and heterozygous mice, displayed a 7-9.7p100 decrease in lifespan, reduced spontaneous locomotor activity, and no lifespan increase when reared in an enriched environment | |
expression of the gene Adcy1, is downregulated in mice lacking Drd4 |